{
  "main_header": {
    "sid": 233635,
    "name": "Johnson Pharma",
    "stock_name": "Johnson Pharma",
    "full_name": "Johnson Pharmacare Ltd",
    "name_url": "stocks-analysis/johnson-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "0.61",
    "chg": -0.02,
    "chgp": "-3.17%",
    "dir": -1,
    "prev_price": "0.63",
    "mcapval": "35.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 532154,
    "symbol": "",
    "ind_name": "Diversified Commercial Services",
    "ind_code": 49,
    "indexname": "",
    "isin": "INE560F01022",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "18.51 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/johnson-pharma-233635-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Johnson Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-johnson-pharma-fallingrising-3742322",
        "imagepath": "",
        "date": "2025-12-03 00:27:24",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Stock Performance Relative to Benchmarks</strong></p>\n<p>Johnson Pharmacare's share price has exhibited a marked decline over the past year and beyond, significantly lagging behind the Sensex. While the benchmark index has delivered a positive return of 6.1% over the last 12 months, Johnson Pharmacare's stock has fallen by nearly 49.6% during the same period. This stark contrast highlights the stock's vulnerability amid a generally bullish market environment.</p>\n<p>Year-to-date figures further underscore this trend, with the stock down 47.4% compared to the Sensex's 8.96% gain. Even over a three-year horizon, the stock has declined by 15.5%, whereas the Sensex has surged by over 35%. Despite a notable five-year gain of 131.5%, outperforming the Sensex's 90.8% rise, the recent trajectory poi..."
      },
      {
        "title": "How has been the historical performance of Johnson Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-johnson-pharma-3702762",
        "imagepath": "",
        "date": "2025-11-14 23:32:07",
        "description": "Answer:\nThe historical performance of Johnson Pharma shows significant fluctuations in revenue and profitability over the years, with a notable decline in recent periods.\n\nBreakdown:\nJohnson Pharma's net sales peaked at 3.26 Cr in March 2022 but have since dropped to 0.00 Cr in March 2025. Total operating income followed a similar trend, decreasing from 3.26 Cr in March 2022 to 0.00 Cr in March 2025. The company experienced an operating profit of 0.13 Cr in March 2022, but this turned negative, resulting in an operating loss of 0.41 Cr by March 2025. Profit before tax also saw a decline, moving from a profit of 0.13 Cr in March 2022 to a loss of 0.58 Cr in March 2025. The profit after tax mirrored this trend, with losses increasing from 0.10 Cr in March 2022 to 0.58 Cr in March 2025. Total assets decreased from 59.98 Cr in March 2022 to 57.93 Cr in March 2025, while total liabilities also fell from 59.98 Cr..."
      },
      {
        "title": "When is the next results date for Johnson Pharma?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-johnson-pharma-3698882",
        "imagepath": "",
        "date": "2025-11-13 23:15:34",
        "description": "The next results date for Johnson Pharma is scheduled for 14 November 2025...."
      }
    ],
    "total": 78,
    "sid": "233635",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/johnson-pharmacare-233635"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Resignation of Director",
      "datetime": "31-Jan-2026",
      "details": "Board Approved the Resignation of Mr. Umesh Kumar (DIN: 07015921) as an Additional & Executive Director",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Meeting Of Board Of Directors Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.",
      "datetime": "31-Jan-2026",
      "details": "The Board has appointed Ms. Babita (DIN: 09064124) as a Non-Executive & Independent Director of the Company w.e.f 31st January 2026 a brief profile pursuant to SEBI Circular dated CIR/CFD/CMD/4/2015 dated September 09 2015 is enclosed as (Attached herewith as Annexure) Further Ms. Babita (DIN: 09064124) is not related to the Directors or Key Managerial Personnel of the Company and is also not debarred from holding the office of Director by virtue of any SEBI order or any other authority. 2. The Board has considered and approved resignation of Mr. Umesh Kumar (DIN: 07015921) as an Additional & Executive Director of the Company w.e.f 31st January 2026 on account of personal reasons and unavoidable reason.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "31-Jan-2026",
      "details": "Board Approved the appointment of Babita as an Non Executive & Independent Director w.e.f. 31st January 2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Johnson Pharmacare Ltd has announced <strong>1:10</strong> stock split, ex-date: 05 Jan 22",
          "dt": "2022-01-05",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Johnson Pharmacare Ltd has announced <strong>1:10</strong> bonus issue, ex-date: 07 Apr 22",
          "dt": "2022-04-07",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Johnson Pharma falling/rising?

2025-12-03 00:27:24

Stock Performance Relative to Benchmarks Johnson Pharmacare's share price has exhibited a marked decline over the past year and beyond, significantly lagging behind the Sensex. While the benchmark index has delivered a positive return of 6.1% over the last 12 months, Johnson Pharmacare's stock has fallen by nearly 49.6% during the same period. This stark contrast highlights the stock's vulnerability amid a generally bullish market environment. Year-to-date figures further underscore this trend, with the stock down 47.4% compared to the Sensex's 8.96% gain. Even over a three-year horizon, the stock has declined by 15.5%, whereas the Sensex has surged by over 35%. Despite a notable five-year gain of 131.5%, outperforming the Sensex's 90.8% rise, the recent trajectory poi...

Read More

How has been the historical performance of Johnson Pharma?

2025-11-14 23:32:07

Answer: The historical performance of Johnson Pharma shows significant fluctuations in revenue and profitability over the years, with a notable decline in recent periods. Breakdown: Johnson Pharma's net sales peaked at 3.26 Cr in March 2022 but have since dropped to 0.00 Cr in March 2025. Total operating income followed a similar trend, decreasing from 3.26 Cr in March 2022 to 0.00 Cr in March 2025. The company experienced an operating profit of 0.13 Cr in March 2022, but this turned negative, resulting in an operating loss of 0.41 Cr by March 2025. Profit before tax also saw a decline, moving from a profit of 0.13 Cr in March 2022 to a loss of 0.58 Cr in March 2025. The profit after tax mirrored this trend, with losses increasing from 0.10 Cr in March 2022 to 0.58 Cr in March 2025. Total assets decreased from 59.98 Cr in March 2022 to 57.93 Cr in March 2025, while total liabilities also fell from 59.98 Cr...

Read More

When is the next results date for Johnson Pharma?

2025-11-13 23:15:34

The next results date for Johnson Pharma is scheduled for 14 November 2025....

Read More

View All News